Aspira Women's Health (AWH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual Meeting scheduled for June 17, 2026, to vote on director elections, executive compensation, stock plan amendment, and auditor ratification.
Record date for voting is April 20, 2026, with 43,500,411 shares outstanding.
Proxy materials and annual report are available online; voting encouraged by internet, phone, or mail.
Voting matters and shareholder proposals
Six director nominees up for election for one-year terms expiring at the 2027 meeting.
Advisory vote on executive compensation (say-on-pay) to be held.
Proposal to amend the 2019 Stock Incentive Plan to increase authorized shares by 5,000,000.
Ratification of BDO USA, P.C. as independent auditor for 2026.
Shareholder proposals for 2027 must be submitted by December 24, 2026, for proxy inclusion.
Board of directors and corporate governance
Board consists of six members with diverse backgrounds in healthcare, finance, and law.
Board leadership structure separates Chair and CEO roles to reinforce independence.
Committees: Audit, Compensation, and Nominating & Governance, all with independent members.
Board and committee meetings held regularly; most directors attended at least 75% of meetings.
Insider trading and hedging prohibited; Dodd-Frank compliant clawback policy in place.
Latest events from Aspira Women's Health
- Revenue fell 15% year-over-year, with improved net loss but ongoing liquidity concerns.AWH
Q2 2026 - Director ownership corrected; largest holder owns 14.1%; proxy votes remain valid.AWH
Proxy filing - AI-driven diagnostics improve detection and reduce surgeries in women's health.AWH
Investor presentation - Net income reached $676,000 despite a 14% revenue drop, but liquidity risks persist.AWH
Q1 2026 - Director elections, executive pay, stock plan amendment, and auditor ratification up for vote.AWH
Proxy filing - Flat revenue, improved margins, and halved operating loss, but significant going concern risk remains.AWH
Q4 2025 - AI-driven diagnostics advance women's health, improving outcomes and financial performance.AWH
Investor presentation - $10M ARPA-H funding accelerates AI diagnostics for ovarian cancer and endometriosis.AWH
Investor Day 2024 - Q2 2024 saw 3% higher OvaSuite test volume, 48% OvaWatch growth, and new funding amid ongoing losses.AWH
Q2 2024